Accurate identifying prostate cancer (PC) from benign prostatic hyperplasia (BPH) is of great significance for timely and proper treatment. Amide proton transfer (APT) is a novel MRI method sensitive to several kinds of cancers. mDIXON-Quant is a powerful quantitive technique for simultaneous fat quantification and R2* mapping, which can reflect the tissue contents and properties. This study aims to assess the diagnostic performance of APT and mDIXON-Quant on differentiating prostate cancers and benign prostate hyperplasia. Results indicate that the combination of APT and mDIXON-Quant can enhance the differential diagnosis of PC and BPH.